Dashboard
1
Poor Management Efficiency with a low ROCE of 2.64%
- The company has been able to generate a Return on Capital Employed (avg) of 2.64% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Poor long term growth as Net Sales has grown by an annual rate of 17.19% and Operating profit at -0.81% over the last 5 years
4
The company has declared Positive results for the last 3 consecutive quarters
5
With ROE of 2.86%, it has a expensive valuation with a 1.50 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,782 Million (Mid Cap)
52.00
NA
0.00%
0.55
2.86%
1.50
Revenue and Profits:
Net Sales:
887 Million
(Quarterly Results - Jun 2025)
Net Profit:
44 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.63%
0%
-3.63%
6 Months
37.8%
0%
37.8%
1 Year
37.2%
0%
37.2%
2 Years
57.92%
0%
57.92%
3 Years
19.48%
0%
19.48%
4 Years
39.0%
0%
39.0%
5 Years
8.69%
0%
8.69%
Brother Enterprises Holding Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.19%
EBIT Growth (5y)
-0.81%
EBIT to Interest (avg)
2.14
Debt to EBITDA (avg)
4.50
Net Debt to Equity (avg)
0.57
Sales to Capital Employed (avg)
0.62
Tax Ratio
16.48%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.64%
ROE (avg)
2.80%
Valuation key factors
Factor
Value
P/E Ratio
52
Industry P/E
Price to Book Value
1.50
EV to EBIT
46.01
EV to EBITDA
13.12
EV to Capital Employed
1.32
EV to Sales
1.88
PEG Ratio
0.37
Dividend Yield
NA
ROCE (Latest)
2.88%
ROE (Latest)
2.86%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
886.80
912.50
-2.82%
Operating Profit (PBDIT) excl Other Income
152.60
122.30
24.78%
Interest
14.00
14.10
-0.71%
Exceptional Items
0.00
0.00
Consolidate Net Profit
43.60
20.90
108.61%
Operating Profit Margin (Excl OI)
75.80%
40.40%
3.54%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -2.82% vs 9.33% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 108.61% vs 151.81% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,420.30
2,801.80
22.08%
Operating Profit (PBDIT) excl Other Income
439.70
187.10
135.01%
Interest
60.60
80.00
-24.25%
Exceptional Items
-2.30
2.20
-204.55%
Consolidate Net Profit
40.80
-175.50
123.25%
Operating Profit Margin (Excl OI)
24.70%
-50.20%
7.49%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 22.08% vs -17.32% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 123.25% vs -157.43% in Dec 2023
About Brother Enterprises Holding Co., Ltd. 
Brother Enterprises Holding Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






